openPR Logo
Press release

Chronic Hepatitis B Virus Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Ascletis Pharma, Shanghai HEP Pharma, Romark Laboratories, Qilu Pharma

09-15-2025 03:34 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Chronic Hepatitis B Virus Pipeline 2025: MOA, ROA, FDA-Approved

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Chronic Hepatitis B Virus pipeline constitutes 55+ key companies continuously working towards developing 60+ Chronic Hepatitis B Virus treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Chronic Hepatitis B Virus Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Hepatitis B Virus Market.

The Chronic Hepatitis B Virus Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Chronic Hepatitis B Virus Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Chronic Hepatitis B Virus treatment therapies with a considerable amount of success over the years.

*
Chronic Hepatitis B Virus companies working in the treatment market are Arbutus Biopharma, GSK/Ionis Pharmaceuticals, Vir Biotechnology, Dong-A ST Co., Ltd., Barinthus Biotherapeutics, GC Biopharma Corp, Brii Biosciences Limited, Vir Biotechnology, Inc., Arbutus Biopharma Corporation, Erasmus Medical Center, Daewoong Pharmaceutical Co., Ascletis Pharmaceuticals, Gilead Sciences, Fujian Akeylink Biotechnology, Chia Tai Tianqing Pharma, Janssen Research & Development, LLC, Hoffmann-La Roche, Chengdu Suncadia Medicine, Suzhou Ribo Life Science, Arbutus Biopharma Corporation, Ascentage Pharma Group, and others, are developing therapies for the Chronic Hepatitis B Virus treatment

*
Emerging Chronic Hepatitis B Virus therapies in the different phases of clinical trials are- AB-729, Bepirovirsen, Elebsiran, GSK3965193, DA-2803, ChAdOx1-HBV, Undiluted I.V.-Hepabig inj(GC5103), PEG-IFN, VIR-3434, AB-729, ISA104, Vemliver tablet, ASC22, TAF, GST-HG131, TQA3605 tablets, JNJ-73763989, Nucleos(t)ide (NUC), HRS9950 tablets, RBD1016, Imdusiran, APG-1387, and others are expected to have a significant impact on the Chronic Hepatitis B Virus market in the coming years.

*
For Imdusiran (AB-729), the primary endpoints included the incidence and severity of treatment-emergent adverse events (TEAEs), discontinuations due to adverse events (AEs), and lab abnormalities following treatment with AB-729 plus Peg-IFN-2a.

*
The main endpoint for GSK3228836 (Bepirovirsen) is the proportion of participants achieving a functional cure (FC) with baseline HBsAg less than or equal to 3000 IU/mL.

*
In July 2025, TherVacB, an innovative therapeutic vaccine for chronic hepatitis B developed by Helmholtz Munich in partnership with the German Center for Infection Research (DZIF), has advanced into its first patient clinical trial. After completing a successful Phase Ia study in healthy volunteers-showing good safety and promising immune responses-the program has now moved into a multi-center Phase Ib/IIa trial, with the first patient enrolled in June 2025.

*
In June 2025, TherVacB, an innovative therapeutic vaccine for chronic hepatitis B developed by Helmholtz Munich in partnership with the German Center for Infection Research (DZIF), began its first clinical trial in patients. After a successful Phase Ia trial in healthy volunteers, which showed a favorable safety profile and induced the intended immune responses, the study has advanced to a multi-center Phase Ib/IIa trial, with the first patient enrolled in June 2025.

*
In May 2025, interim data from a Phase 2b clinical trial showed that AHB-137, Ausperbio's investigational therapy, safely and effectively suppressed the hepatitis B virus (HBV) in individuals with chronic hepatitis B. These encouraging results, consistent with earlier findings from an ongoing Phase 1/2a trial (NCT06115993), were presented during a poster session at the annual European Association for the Study of the Liver Congress.

*
In May 2025, Vir Biotechnology's combination therapy aimed at a "functional cure" for hepatitis B did not meet efficacy endpoints in a Phase II trial. Data from the 24-week mark of the ongoing MARCH Phase II study (NCT04856085) showed that only 17% (3/18) of patients receiving tobevibart and elebsiran alone, and 21% (3/14) of those receiving the combination with peginterferon, achieved undetectable hepatitis B surface antigen (HBsAg) among patients with baseline HBsAg



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Chronic Hepatitis B Virus Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Ascletis Pharma, Shanghai HEP Pharma, Romark Laboratories, Qilu Pharma here

News-ID: 4183230 • Views:

More Releases from ABNewswire

Kolega.ai Launches Autonomous AI Software Engineer, Achieves Breakeven Status with Significant Revenue Commitments in Launch Year
Kolega.ai Launches Autonomous AI Software Engineer, Achieves Breakeven Status wi …
Kolega.ai emerges from stealth with a new category of AI developer, an Autonomous Agent for Enterprise Software Engineering. The company announces it has achieved breakeven status and secured significant multi-year revenue commitments, signaling a new era of capital-efficient AI innovation. JERSEY, CHANNEL ISLANDS - Kolega.ai today announced its official launch, unveiling an Autonomous Agent for Software Engineering capable of executing the entire software development lifecycle (SDLC) from simple well structured requirements.
Viltrox AF 85mm F2.0 EVO FE Mount Lens: A Compact, Precision-built Powerhouse
Viltrox AF 85mm F2.0 EVO FE Mount Lens: A Compact, Precision-built Powerhouse
The essential lens, redefined: New EVO optics deliver spectacular results Image: https://www.abnewswire.com/upload/2025/10/f072fe4958b6681fd8535006ec48061b.jpg Shenzhen, China - October 20th, 2025 - Viltrox is pleased to announce the AF 85mm F2.0 EVO FE lens, launching the company's new EVO lineup for creators seeking a perfect balance of performance, portability, and precision. Combining an entirely redesigned, enhanced optical layout with advanced autofocus technology, the lens brings exceptional sharpness, refined color rendering, and intuitive control to photographers
Wilson Disease Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Deep Genomics Inc, DepYmed Inc, Enveda Biosciences Inc, Generation Bio Co
Wilson Disease Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Tri …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Wilson Disease pipeline constitutes 5+ key companies continuously working towards developing 5+ Wilson Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Wilson Disease Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/wilson-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Wilson Disease Market. The Wilson Disease Pipeline report
Hedgie Bartol Joins Alpha Vision as Vice President of Retail Business Development, Elevating AI-Powered Safety and Security for Retailers
Hedgie Bartol Joins Alpha Vision as Vice President of Retail Business Developmen …
Alpha Vision has appointed Hedgie Bartol-LPQ, LPC as Vice President of Retail Business Development, advancing its mission to drive AI-powered physical security innovation in retail. With nearly 30 years of leadership at Indyme, Auror, Axis, Milestone, and Diebold, Bartol will lead retail strategy to help major retailers leverage Alpha Vision's Physical Super Intelligence Platform to reduce theft, enhance safety, and transform operations through real-time AI threat detection. Sunnyvale, CA - October

All 5 Releases


More Releases for Vir

Influenza A Market: Epidemiology, Therapies, Companies, DelveInsight | Cidara Th …
The influenza A market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM influenza A market size from 2020 to 2034. The report also covers current influenza A treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential. Influenza A therapies, such as XOFLUZA, RAPIVAB, FLUAD QUADRIVALENT, mRNA-1010, CD388, Flu Pandemic mRNA (GSK4382276A), CC-42344, and others, are
Influenza A Market: Epidemiology, Therapies, Companies, DelveInsight | Cidara Th …
Influenza A therapies, such as XOFLUZA, RAPIVAB, FLUAD QUADRIVALENT, mRNA-1010, CD388, Flu Pandemic mRNA (GSK4382276A), CC-42344, and others, are expected to boost the Influenza A Market in the upcoming years. DelveInsight has launched a new report on "Influenza A - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Influenza A, historical and forecasted epidemiology as well as the Influenza A market trends in the United States,
Investigation for NASDAQ: VIR Investors over possible Wrongdoing at Vir Biotechn …
An investigation was announced over potential breaches of fiduciary duties by certain directors at Vir Biotechnology, Inc. Investors who purchased shares of Vir Biotechnology, Inc. (NASDAQ: VIR) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Vir Biotechnology directors breached their fiduciary duties and caused damage to the company and its shareholders. San Francisco, CA based
SOFTWARE-DEFINED NETWORKING AND NETWORK FUTUALIZATION MARKET knowNCTION VIR indu …
“The SDN and NFV is picking up noticeable quality because of the developing mechanical progressions in systems administration and server farm union. SDN is a momentous systems administration design, which is ready to totally alter the current systems administration and server farm foundation. The SDN building structure is set to reclassify the systems administration framework to meet the developing number of system clients devouring a high data transfer capacity. With
Investigation announced for Investors in shares of Vir Biotechnology, Inc. (NASD …
Vir Biotechnology, Inc is under investigation concerning potential securities laws violations in connection with certain financial statements. Investors who purchased shares of Vir Biotechnology, Inc. (NASDAQ: VIR), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Vir Biotechnology, Inc. regarding its business, its prospects and its operations were materially false
Global Balancing Valves Market 2017 - IMI Hydronic, Danfoss, Frese A/S, Caleffi, …
"A balancing valve is a measurement and regulation device. Balancing valves are used in pressurized piping applications, such as HVAC and gas movement applications. The main purpose of a balancing valve is generally to create a consistent output pressure to a system from an inconsistent input pressure from a different system." Scope of the Report: This report focuses on the Balancing Valves in Global market, especially in North America, Europe and Asia-Pacific,